Regional Anesthesia for Thoracoscopic Surgery
RATS
1 other identifier
observational
150
1 country
1
Brief Summary
Aim of the study is to evaluate different regional anesthesia regimes for thoracoscopic surgery to evaluate their efficiency in (postoperative) pain control. Three regional anesthesia forms are evaluated: thoracic epidural anesthesia, (ultrasound-guided) serratus-anterior-plane-block an local infiltration with local anesthetic at the site of performing the thoracoscopy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jul 2014
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2014
CompletedFirst Submitted
Initial submission to the registry
November 28, 2014
CompletedFirst Posted
Study publicly available on registry
December 3, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2016
CompletedDecember 3, 2014
November 1, 2014
11 months
November 28, 2014
December 2, 2014
Conditions
Outcome Measures
Primary Outcomes (1)
Postoperative Pain (visual analog scale)
the postoperative Pain, evaluated with a visual analog scale (VAS), was obtained in the first 48 hours postoperatively after thoracoscopic surgery
48 hours postoperative
Study Arms (3)
Epidural anesthesia
Patients receiving thoracic epidural anesthesia for thoracoscopic surgery. Standard regimen with 8-20 ml Ropivacaine 0,5% in the epidural catheter. Postopertive Ropivacaine 0,2% 6 ml/h via catheter were administered.
Serratus-anterior-plane-Block
Patients receiving (ultrasound-guided) Serratus-anterior-plane-Block for thoracoscopic surgery. Standard regimen up to 20 ml Ropivacaine 0,5%, were installed. Postopertive Ropivacaine 0,2% 6 ml/h via catheter were administered.
Local infiltration
Patients receiving local infiltration with up to 20 ml Ropivacaine 0,5% for thoracoscopic surgery (at the site of thoracoscopy)
Eligibility Criteria
Patients scheduled for thoracoscopic surgery ASA 1-3
You may qualify if:
- Patients scheduled for thoracoscopic surgery
- ASA 1-3
You may not qualify if:
- ASA 4 and 5
- Age under 18 and over 80
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University Hospital Munich, Marchioninistr. 15
Munich, 81377, Germany
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Philip M Lang, M.D., Ph. D.
Attending
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Target Duration
- 3 Days
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant professor
Study Record Dates
First Submitted
November 28, 2014
First Posted
December 3, 2014
Study Start
July 1, 2014
Primary Completion
June 1, 2015
Study Completion
June 1, 2016
Last Updated
December 3, 2014
Record last verified: 2014-11